364 reports of this reaction
2.5% of all DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE reports
#6 most reported adverse reaction
INTRAOCULAR PRESSURE INCREASED is the #6 most commonly reported adverse reaction for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, manufactured by Thea Pharma Inc.. There are 364 FDA adverse event reports linking DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE to INTRAOCULAR PRESSURE INCREASED. This represents approximately 2.5% of all 14,333 adverse event reports for this drug.
Patients taking DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE who experience intraocular pressure increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INTRAOCULAR PRESSURE INCREASED is a less commonly reported adverse event for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, but still significant enough to appear in the safety profile.
In addition to intraocular pressure increased, the following adverse reactions have been reported for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE:
The following drugs have also been linked to intraocular pressure increased in FDA adverse event reports:
INTRAOCULAR PRESSURE INCREASED has been reported as an adverse event in 364 FDA reports for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INTRAOCULAR PRESSURE INCREASED accounts for approximately 2.5% of all adverse event reports for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, making it a notable side effect.
If you experience intraocular pressure increased while taking DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.